Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Fallers
Why these ASX shares are sinking lower today
Share Gainers
Why these 4 ASX shares are pushing higher today
⏸️ Famous Investors
One of Australia's richest people reveals his latest share ideas
Share Fallers
Why these 4 ASX shares are sinking lower today
52-Week Highs
Is it too late to buy these market-beaters?
Share Gainers
Why these 4 ASX shares are jumping higher today
Share Gainers
Why these 4 ASX shares are on the rise today
Share Market News
Top broker makes FY19 picks
Share Gainers
Why these 4 ASX shares are surging higher today
Share Gainers
Race Oncology Ltd shares rocket on "game changing" outcome
Share Gainers
Why Mesoblast limited (ASX:MSB) shares could rocket higher today
Share Market News
5 things to watch on the ASX on Wednesday
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
